AR056645A1 - Compuestos de urea sustituida inhibidores de enzimas chk1 . - Google Patents
Compuestos de urea sustituida inhibidores de enzimas chk1 .Info
- Publication number
- AR056645A1 AR056645A1 ARP060101226A ARP060101226A AR056645A1 AR 056645 A1 AR056645 A1 AR 056645A1 AR P060101226 A ARP060101226 A AR P060101226A AR P060101226 A ARP060101226 A AR P060101226A AR 056645 A1 AR056645 A1 AR 056645A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- 3alkyl
- halogen
- ring
- chk1
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyridine Compounds (AREA)
Abstract
Composiciones farmacéuticas que los contienen y usos terapéuticos en el tratamiento del cáncer. reivindicacion 1: Un compuesto caracterizado porque responde a la formula estructural (1) donde R1 es halogeno, alquilo C1-3, CN y CF3; R2 es H, alquilo C1-3, CN, Oalquilo C1-3, halogeno, o N(Rb)2, donde Rb, independientemente, es H o alquilo C1-3; R3 es un anillo heterocíclico saturado de 6 o 7 miembros que contiene un grupo cíclico N-Ra y a sea un segundo grupo cíclico N-Ra, un O en el anillo, o un S en el anillo, donde Ra, independientemente, es H, alquilo C1-3, CH2CN, o CH2CH2CN, y donde R3 opcionalmente está sustituido con oxo(=O); R4 es H, alquilo C1-3, Oalquilo C1-3, Salquilo C1-3o, N(Rb)2, NRbC(=O)alquilo C1-3, o un anillo heterocíclico saturado de 5 o 6 miembros que contiene un grupo N-Ra y un anillo opcionalmente sustituido con entre uno y tres grupos alquilo C1-3; o R2 y R4 se tomen junto con los carbonos a los cuales están unidos para formar un anillo carbocíclico saturado e entre 5 y 7 miembros; y R5 es H o halogeno; con la salvedad de que por lo menos uno de R2 y R4 n sea H y que cuando R5 es halogeno, R2 o R4 es H; o una sal, prodroga, o solvato de los mismos aceptable para uso farmacéutico.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US66602605P | 2005-03-29 | 2005-03-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR056645A1 true AR056645A1 (es) | 2007-10-17 |
Family
ID=36677174
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP060101226A AR056645A1 (es) | 2005-03-29 | 2006-03-29 | Compuestos de urea sustituida inhibidores de enzimas chk1 . |
Country Status (32)
| Country | Link |
|---|---|
| US (1) | US8093244B2 (es) |
| EP (2) | EP2330105A1 (es) |
| JP (2) | JP5117374B2 (es) |
| KR (2) | KR100912998B1 (es) |
| CN (2) | CN102219784A (es) |
| AR (1) | AR056645A1 (es) |
| AT (1) | ATE490248T1 (es) |
| AU (1) | AU2006230337B2 (es) |
| BR (1) | BRPI0609667A2 (es) |
| CA (1) | CA2602199C (es) |
| CR (1) | CR9395A (es) |
| CY (1) | CY1111240T1 (es) |
| DE (1) | DE602006018590D1 (es) |
| DK (1) | DK1869020T3 (es) |
| EA (1) | EA011287B1 (es) |
| ES (1) | ES2356068T3 (es) |
| HK (1) | HK1119670A1 (es) |
| HR (1) | HRP20100678T1 (es) |
| IL (1) | IL185481A0 (es) |
| MA (1) | MA29439B1 (es) |
| MX (1) | MX2007012116A (es) |
| NO (1) | NO20074944L (es) |
| NZ (1) | NZ561458A (es) |
| PL (1) | PL1869020T3 (es) |
| PT (1) | PT1869020E (es) |
| RS (1) | RS51616B (es) |
| SI (1) | SI1869020T1 (es) |
| TN (1) | TNSN07369A1 (es) |
| TW (1) | TWI375559B (es) |
| UA (1) | UA92164C2 (es) |
| WO (1) | WO2006105262A1 (es) |
| ZA (1) | ZA200707715B (es) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008067027A2 (en) | 2006-10-20 | 2008-06-05 | Icos Corporation | Compositions of chkl inhibitors and cyclodextrin |
| CN101200429B (zh) * | 2006-12-13 | 2012-08-22 | 上海睿智化学研究有限公司 | 2-硝基-4,5-二卤代苯酚类和2-氨基-4,5-二卤代苯酚类及其盐及其合成方法 |
| GB201008005D0 (en) | 2010-05-13 | 2010-06-30 | Sentinel Oncology Ltd | Pharmaceutical compounds |
| CN112472699A (zh) | 2013-07-26 | 2021-03-12 | 种族肿瘤学公司 | 改善比生群及衍生物的治疗益处的组合方法 |
| PT3157566T (pt) | 2014-06-17 | 2019-07-11 | Vertex Pharma | Método para tratamento de cancro utilizando uma combinação de inibidores chk1 e atr |
| TW201702218A (zh) | 2014-12-12 | 2017-01-16 | 美國杰克森實驗室 | 關於治療癌症、自體免疫疾病及神經退化性疾病之組合物及方法 |
| CA3000684A1 (en) | 2015-09-30 | 2017-04-06 | Vertex Pharmaceuticals Incorporated | Method for treating cancer using a combination of dna damaging agents and atr inhibitors |
| EP3411036B1 (en) | 2016-02-04 | 2021-12-29 | Pharmaengine, Inc. | 3,5-disubstituted pyrazoles useful as checkpoint kinase 1 (chk1) inhibitors, and their preparations and applications |
| KR20230042756A (ko) | 2016-03-15 | 2023-03-29 | 오리존 지노믹스 에스.에이. | 고형 종양의 치료에 사용하기 위한 lsd1 억제제의 조합물 |
| MX2019011506A (es) * | 2017-03-31 | 2019-11-01 | Seattle Genetics Inc | Inhibicion de cinasa 1 de punto de control (chk1) para el tratamiento de cancer. |
| EP3461480A1 (en) | 2017-09-27 | 2019-04-03 | Onxeo | Combination of a dna damage response cell cycle checkpoint inhibitors and belinostat for treating cancer |
| WO2021183973A1 (en) * | 2020-03-13 | 2021-09-16 | Research Development Foundation | Methods for diagnosing and treating cancers |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4293552A (en) | 1978-02-27 | 1981-10-06 | Eli Lilly And Company | Novel 1-(mono-o-substituted benzoyl)-3-(substituted pyrazinyl) ureas |
| US6174993B1 (en) | 1997-05-21 | 2001-01-16 | The Children's Medical Center Corp. | Short peptides which selectively modulate the activity of serine/threonine kinases |
| GB9718952D0 (en) | 1997-09-05 | 1997-11-12 | Medical Res Council | Mammalian chk1 effector cell cycle checkpoint protein kinase materials and methods |
| US6218109B1 (en) | 1997-09-05 | 2001-04-17 | Baylor College Of Medicine | Mammalian checkpoint genes and proteins |
| CN1278725A (zh) | 1997-10-06 | 2001-01-03 | 巴斯福股份公司 | 茚并[1,2－c]－、萘并[1,2－c]－和苯并[6,7]芳庚并[1,2－c]吡唑类衍生物 |
| EP1135135A4 (en) | 1998-09-18 | 2006-08-09 | Smithkline Beecham Corp | CHK1 KINASE INHIBITORS |
| YU54202A (sh) | 2000-01-18 | 2006-01-16 | Agouron Pharmaceuticals Inc. | Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije |
| HN2001000008A (es) | 2000-01-21 | 2003-12-11 | Inc Agouron Pharmaceuticals | Compuesto de amida y composiciones farmaceuticas para inhibir proteinquinasas, y su modo de empleo |
| AU3974001A (en) | 2000-02-03 | 2001-08-14 | Ali R. Fattaey | Method and reagent for the inhibition of checkpoint kinase-1 (chk 1) enzyme |
| WO2001062900A1 (en) | 2000-02-25 | 2001-08-30 | The Regents Of The University Of California. | Scytonemin and methods of using thereof |
| US6211164B1 (en) | 2000-03-10 | 2001-04-03 | Abbott Laboratories | Antisense oligonucleotides of the human chk1 gene and uses thereof |
| US6534691B2 (en) | 2000-07-18 | 2003-03-18 | E. I. Du Pont De Nemours And Company | Manufacturing process for α-olefins |
| ATE295354T1 (de) | 2000-08-18 | 2005-05-15 | Agouron Pharma | Heterozyklische-hydroximino-fluorene und ihre verwendung zur inhibierung von proteinkinasen |
| MXPA03006478A (es) | 2001-01-26 | 2003-09-22 | Pharmacia Italia Spa | Derivados de cromano, procedimiento para su preparacion y su uso como agentes antitumorales. |
| UA76977C2 (en) * | 2001-03-02 | 2006-10-16 | Icos Corp | Aryl- and heteroaryl substituted chk1 inhibitors and their use as radiosensitizers and chemosensitizers |
| US7064215B2 (en) | 2001-07-03 | 2006-06-20 | Chiron Corporation | Indazole benzimidazole compounds |
| US7166639B2 (en) | 2001-10-04 | 2007-01-23 | Smithkline Beecham Corporation | NF-κB inhibitors |
| WO2003029241A1 (en) | 2001-10-04 | 2003-04-10 | Smithkline Beecham Corporation | Chk1 kinase inhibitors |
| WO2003028731A1 (en) | 2001-10-04 | 2003-04-10 | Smithkline Beecham Corporation | Chk1 kinase inhibitors |
| WO2003028724A1 (en) | 2001-10-04 | 2003-04-10 | Smithkline Beecham Corporation | Chk1 kinase inhibitors |
| EP1444010A2 (en) | 2001-10-30 | 2004-08-11 | Pharmacia Corporation | Heteroaromatic carboxamide derivatives for the treatment of inflammation |
| US20030119839A1 (en) | 2001-12-13 | 2003-06-26 | Nan-Horng Lin | Protein kinase inhibitors |
| US20030187026A1 (en) | 2001-12-13 | 2003-10-02 | Qun Li | Kinase inhibitors |
| AU2003224341A1 (en) | 2002-04-26 | 2003-11-10 | Warner-Lambert Company Llc | Inhibitors of checkpoint kinases (wee1 and chk1) |
| US7202244B2 (en) * | 2002-05-29 | 2007-04-10 | Millennium Pharmaceuticals, Inc. | Chk-1 inhibitors |
| US7056925B2 (en) * | 2002-08-13 | 2006-06-06 | Abbott Laboratories | Urea kinase inhibitors |
| US20040034038A1 (en) | 2002-08-13 | 2004-02-19 | Goaquan Li | Urea kinase inhibitors |
| AU2003288899B2 (en) | 2002-08-23 | 2009-09-03 | Novartis Vaccines And Diagnostics, Inc. | Benzimidazole quinolinones and uses thereof |
| MXPA05005547A (es) | 2002-11-28 | 2005-07-26 | Schering Ag | Pirimidinas inhibidoras de chk, pdk y akt, su produccion y uso como agentes farmaceuticos. |
| ATE404564T1 (de) | 2003-01-09 | 2008-08-15 | Pfizer | Diazepinoindolderivate als kinaseinhibitoren |
| WO2006012308A1 (en) | 2004-06-25 | 2006-02-02 | Icos Corporation | Bisarylurea derivatives useful for inhibiting chk1 |
| CA2679908A1 (en) | 2009-09-23 | 2011-03-23 | Shell Internationale Research Maatschappij B.V. | Closed loop solvent extraction process for oil sands |
| CN104407475B (zh) | 2014-12-04 | 2017-04-05 | 厦门天马微电子有限公司 | 液晶显示面板 |
-
2006
- 2006-03-29 SI SI200630870T patent/SI1869020T1/sl unknown
- 2006-03-29 DE DE602006018590T patent/DE602006018590D1/de active Active
- 2006-03-29 DK DK06748900.5T patent/DK1869020T3/da active
- 2006-03-29 KR KR1020077022281A patent/KR100912998B1/ko not_active IP Right Cessation
- 2006-03-29 AU AU2006230337A patent/AU2006230337B2/en not_active Ceased
- 2006-03-29 JP JP2008504337A patent/JP5117374B2/ja not_active Expired - Fee Related
- 2006-03-29 MX MX2007012116A patent/MX2007012116A/es active IP Right Grant
- 2006-03-29 UA UAA200710711A patent/UA92164C2/ru unknown
- 2006-03-29 NZ NZ561458A patent/NZ561458A/en not_active IP Right Cessation
- 2006-03-29 RS RS20110053A patent/RS51616B/en unknown
- 2006-03-29 PT PT06748900T patent/PT1869020E/pt unknown
- 2006-03-29 US US11/908,416 patent/US8093244B2/en not_active Expired - Fee Related
- 2006-03-29 EP EP10189889A patent/EP2330105A1/en not_active Withdrawn
- 2006-03-29 KR KR1020097002925A patent/KR20090031459A/ko not_active Application Discontinuation
- 2006-03-29 TW TW095110859A patent/TWI375559B/zh not_active IP Right Cessation
- 2006-03-29 BR BRPI0609667-0A patent/BRPI0609667A2/pt not_active IP Right Cessation
- 2006-03-29 ES ES06748900T patent/ES2356068T3/es active Active
- 2006-03-29 PL PL06748900T patent/PL1869020T3/pl unknown
- 2006-03-29 CN CN2011101022112A patent/CN102219784A/zh active Pending
- 2006-03-29 CA CA2602199A patent/CA2602199C/en not_active Expired - Fee Related
- 2006-03-29 AT AT06748900T patent/ATE490248T1/de active
- 2006-03-29 EA EA200702094A patent/EA011287B1/ru not_active IP Right Cessation
- 2006-03-29 CN CN2006800101504A patent/CN101151259B/zh not_active Expired - Fee Related
- 2006-03-29 EP EP06748900A patent/EP1869020B1/en active Active
- 2006-03-29 WO PCT/US2006/011584 patent/WO2006105262A1/en active Application Filing
- 2006-03-29 AR ARP060101226A patent/AR056645A1/es unknown
-
2007
- 2007-08-23 IL IL185481A patent/IL185481A0/en unknown
- 2007-09-07 ZA ZA200707715A patent/ZA200707715B/xx unknown
- 2007-09-26 CR CR9395A patent/CR9395A/es unknown
- 2007-09-28 TN TNP2007000369A patent/TNSN07369A1/en unknown
- 2007-10-01 NO NO20074944A patent/NO20074944L/no not_active Application Discontinuation
- 2007-10-26 MA MA30325A patent/MA29439B1/fr unknown
-
2008
- 2008-06-25 HK HK08107066.6A patent/HK1119670A1/xx not_active IP Right Cessation
-
2009
- 2009-05-20 JP JP2009122107A patent/JP2009227682A/ja active Pending
-
2010
- 2010-12-07 HR HR20100678T patent/HRP20100678T1/hr unknown
-
2011
- 2011-02-03 CY CY20111100117T patent/CY1111240T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR056645A1 (es) | Compuestos de urea sustituida inhibidores de enzimas chk1 . | |
| NI200700270A (es) | Derivados benzodioxano y benzodioxolano y usos de los mismos | |
| AR066583A1 (es) | Derivados de 3,3-espiroindolinona | |
| AR059957A1 (es) | DERIVADOS DE ESPIROINDOLINONA, MÉTODOS PARA SU PREPARACIoN, UNA COMPOSICIoN FARMACÉUTICA QUE LOS CONTIENE Y SU USO EN LA FABRICACIoN DE MEDICAMENTOS PARA EL TRATAMIENTO DEL CÁNCER. | |
| AR067757A1 (es) | Derivados de imidazo[4,5-c]piridin-2-ona, composiciones farmaceuticas que los contienen, procedimiento para su preparacion y uso de los mismos como agentes antivirales. | |
| AR063022A1 (es) | Derivados de indol antagonistas del receptor de glucagon, composiciones farmaceuticas que los contienen y usos para tratar diabetes mellitus tipo 2 y estados patologicos relacionados. | |
| CO6251264A2 (es) | Derivados de 1-ciano ciclopropilo como inhibidores de la captesina k | |
| AR079205A1 (es) | Morfolinotiazoles como moduladores alostericos positivos alfa 7 | |
| AR072952A1 (es) | Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso | |
| GT200600518A (es) | Derivados de pirimidina | |
| CL2011002706A1 (es) | Compuestos derivados de 4-(1,3-oxazol-2-il)-1h-indazol; composicion farmaceutica que los comprende; y sus usos en el tratamiento de enfermedades tales como epoc, autoinmunes, asma, entre otras. | |
| GT200600165A (es) | Derivados dihidrobenzofuranos y usos de los mismos | |
| AR049398A1 (es) | Derivados de sulfamato y sulfamida; una composicion farmaceutica que los contiene y su uso en la preparacion de un medicamento util para el tratamiento de la epilepsia y trastornos relacionados. | |
| UY29393A1 (es) | Nuevos derivados de amidas, sales farmacéuticas aceptables, composiciones que los contienen, procedimientos de preparación y aplicaciones. | |
| NI201000011A (es) | Derivados de pirimidina 934. | |
| CO6321153A2 (es) | Derivados de cromeno y cromano y sus usos | |
| AR052902A1 (es) | Derivados de piridazina, composicion farmaceutica que los contiene y su uso como agentes terapeuticos para enfermedades mediadas por la estearoil-coa desaturasa | |
| AR063602A1 (es) | Derivados de espiroindolinona, formulaciones farmaceuticas que los contienen y su uso en la obtencion de un medicamento para el tratamiento de trastornos oncologicos. | |
| AR092270A1 (es) | Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b | |
| PE20070832A1 (es) | Derivados de piridazinona como inhibidores de la tirosina quinasa | |
| AR075729A1 (es) | Derivados de benzofuranilo, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de la obesidad y/o diabetes. | |
| AR047076A1 (es) | Compuestos de pirrolotriazina como inhibidores de tirosina quinasas, composiciones farmaceuticas | |
| AR065280A1 (es) | Agentes antiparasitarios | |
| AR049578A1 (es) | Derivados de hidantoina, procesos de obtencion y composiciones farmaceuticas | |
| UY29703A1 (es) | "inhibidores macrocíclicos del virus de la hepatitis c" |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |